Prediction of Coronary Heart Disease in a Population With High Prevalence of Diabetes and Albuminuria The Strong Heart Study

Size: px
Start display at page:

Download "Prediction of Coronary Heart Disease in a Population With High Prevalence of Diabetes and Albuminuria The Strong Heart Study"

Transcription

1 Prediction of Coronary Heart Disease in a Population With High Prevalence of Diabetes and Albuminuria The Strong Heart Study Elisa T. Lee, PhD; Barbara V. Howard, PhD; Wenyu Wang, PhD; Thomas K. Welty, MD; James M. Galloway, MD; Lyle G. Best, MD; Richard R. Fabsitz, PhD; Ying Zhang, MD, PhD; Jeunliang Yeh, PhD; Richard B. Devereux, MD Background The present article presents equations for the prediction of coronary heart disease (CHD) in a population with high rates of diabetes and albuminuria, derived from data collected in the Strong Heart Study, a longitudinal study of cardiovascular disease in 13 American Indian tribes and communities in Arizona, North and South Dakota, and Oklahoma. Methods and Results Participants of the Strong Heart Study were examined initially in and were monitored with additional examinations and mortality and morbidity surveillance. CHD outcome data through December 2001 showed that age, gender, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol, smoking, diabetes, hypertension, and albuminuria were significant CHD risk factors. Hazard ratios for ages 65 to 75 years, hypertension, LDL cholesterol 160 mg/dl, diabetes, and macroalbuminuria were 2.58, 2.01, 2.44, 1.66, and 2.11 in men and 2.03, 1.69, 2.17, 2.26, and 2.69 in women, compared with ages 45 to 54 years, normal blood pressure, LDL cholesterol 100 mg/dl, no diabetes, and no albuminuria. Prediction equations for CHD and a risk calculator were derived by gender with the use of Cox proportional hazards model and the significant risk factors. The equations provided good discrimination ability, as indicated by a c statistic of 0.70 for men and 0.73 for women. Results from bootstrapping methods indicated good internal validation and calibration. Conclusions A risk calculator has been developed and placed on the Strong Heart Study Web site, which provides predicted risk of CHD in 10 years with input of these risk factors. This may be valuable for diverse populations with high rates of diabetes and albuminuria. (Circulation. 2006;113: ) Key Words: American Indian atherosclerosis coronary disease coronary heart disease epidemiology prediction equation risk factors The prevalence and incidence of coronary heart disease (CHD) and its risk factors have been studied extensively in various populations. The most well-known study is the Framingham Heart Study (FHS), which was initiated in The FHS has developed mathematical equations to predict the risk of CHD 1 on the basis of several of the clinically available risk factors: age, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), blood pressure/hypertension, diabetes, and cigarette smoking. The equations have been used widely for CHD risk appraisal. A recent examination of the validity and transportability of the FHS equations to other ethnic populations found that the FHS equations performed well for predicting CHD events for white and black men and women. For Hispanic and Puerto Rican men and Native American women, the equations also perform well when adjustments for the different risk factor levels and different incidence of CHD are made. 2 Clinical Perspective p 2905 Diabetes is highly prevalent in American Indians, and heart disease has increased rapidly in recent decades 3 to become the leading cause of death in most American Indian populations. 4 The Strong Heart Study (SHS), 5 a longitudinal study Received October 5, 2005; revision received April 17, 2006; accepted May 1, From the Center for American Indian Health Research, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (E.T.L., W.W., Y.Z., J.Y.); MedStar Research Institute, Washington, DC (B.V.H.); Missouri Breaks Industries Research, Inc, Timber Lake, SD (T.K.W., L.G.B.); University of Arizona, Tucson (J.M.G.); Epidemiology and Biometry Program, National Heart, Lung, and Blood Institute, Bethesda, Md (R.R.F.); and Weill Medical College, Cornell University, New York, NY (R.B.D.). The online-only Data Supplement, which contains an appendix, can be found at /DC1. The views expressed in this article are those of the authors and do not necessarily reflect those of the Indian Health Service. Correspondence to Elisa T. Lee, PhD, Center for American Indian Health Research, College of Public Health, University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, OK elisa-lee@ouhsc.edu 2006 American Heart Association, Inc. Circulation is available at DOI: /CIRCULATIONAHA

2 2898 Circulation June 27, 2006 of cardiovascular disease in American Indians, initiated in 1988, has collected data on CHD and potential risk factors since The data provide an excellent opportunity to develop equations to predict CHD risk in individuals without overt CHD on the basis of the levels of CHD risk factors at baseline examination. Our previous analyses showed that risk factors for CHD were similar to those identified in the FHS. However, in the SHS, previous publications showed that albuminuria, fibrinogen, and left ventricular hypertrophy determined by echocardiogram also had a strong association with CHD in the American Indian population. 3 This article presents CHD prediction equations from the SHS by gender, with the use of different sets of significant risk factors identified in the study. These equations were developed on the basis of longitudinal data of the SHS during The primary purpose is to provide physicians who attend American Indians with a tool to predict CHD risk in their patients. A risk calculator (available on the SHS Web site: has been developed for individuals to input their values of the risk factors and instantly obtain a probability of developing CHD in 10 years. This tool should have potential applicability to other populations with high prevalence of diabetes and albuminuria. Methods Study Population and Variables Included The SHS examined a total of 4549 American Indian men and women, aged 45 to 74 years, in 13 Indian tribes/communities in Arizona, North and South Dakota, and Oklahoma at its baseline examination ( ). Of the 4549 participants, 4372 (1722 men and 2650 women) were free of CHD and definite stroke at the time of the baseline examination. Survivors of the cohort were reexamined in and Mortality and morbidity surveillance was also conducted annually. Data from the 4372 participants who were free of CHD and definite stroke at baseline examination were used to develop the prediction equations. The baseline examination included a personal interview and a physical examination. Age and smoking status (yes or no) were obtained from the interview. The physical examination included measurements of height, weight, and sitting systolic (SBP) and diastolic blood pressure (DBP). Body mass index was calculated from height and weight (kg/m 2 ). Hypertension was classified into 3 categories according to the Seventh Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure criteria 6 : normal (SBP 120 mm Hg and DBP 80 mm Hg, not on antihypertensive medication), prehypertension (SBP 120 to 139 mm Hg or DBP 80 to 89 mm Hg, not on antihypertensive medication), and hypertension (SBP 140 mm Hg or DBP 90 mm Hg and/or on antihypertensive medication). Blood was drawn after a 12-hour fast to measure TC, HDL-C, LDL-C, and fasting plasma glucose. A urine sample was taken to measure albumin and creatinine. Laboratory methods were published previously. 5 Diabetes was defined with the use of the 1997 American Diabetes Association criteria, 7 ie, fasting plasma glucose 126 mg/dl (6.99 mmol/l) or receiving insulin or oral hyperglycemic treatment. Albuminuria was determined with the use of the ratio of urinary albumin and creatinine: microalbuminuria if the ratio was 30 and 300 and macroalbuminuria if the ratio was 300. Fibrinogen was measured by the von Clauss method. 8 An electrocardiogram (ECG) was obtained from every participant. The ECGs were read centrally by 3 cardiologists at the Fitzsimmons Medical Center in Denver. In some analyses, age was classified into 3 groups: 45 to 54, 55 to 64, and 65 to 74 years; TC into 3 categories: 200, 200 to 239, 240 mg/dl ( 5.18, 5.18 to 6.21, 6.22 mmol/l); HDL-C into 3 categories: 40, 40 to 59, and 60 mg/dl ( 1.04, 1.04 to 1.54, and 1.55 mmol/l); and LDL-C into 4 categories: 100, 100 to 129, 130 to 159, and 160 mg/dl ( 2.59, 2.59 to 3.35, 3.36 to 4.13, and 4.14 mmol/l). 9 These analyses were intended to provide information on relative hazards among subcategories. In deriving the prediction equations, these risk factors were used as continuous rather than categorical variables. Participants who had previous CHD (definite CHD, definite myocardial infarction [MI], definite ECG-evident MI) or definite stroke before or at the baseline examination were excluded. Those who were free of CHD and definite stroke at baseline examination were followed up. CHD events that occurred during the follow-up period were ascertained by annual mortality and morbidity surveillance or at the second and third examinations. In the annual surveillance, participants were contacted to determine their vital status and, if living, whether any cardiovascular events of interest had occurred since last contact. Medical records were abstracted and CHD death and events were ascertained and confirmed by mortality and morbidity review committees using specific criteria. 10 Data used in this report included fatal and nonfatal CHD events occurring in the 12-year follow-up period from baseline examination through December The completion rates for the follow-up of mortality and morbidity events were 99.8% and 99.2%, respectively. These events were nonfatal definite MI, definite CHD, ECG-evident definite MI, fatal definite MI, definite CHD, possible CHD (87% fatal), and sudden death due to CHD. Detailed definitions of the fatal and nonfatal events were described previously. 4,11 Time to event was calculated from the date of baseline examination to the date of CHD event or last follow-up. If 1 CHD event occurred in the same individual, the earliest date was used as the date of event in calculating the observed time to event. Development of Prediction Equations First, we examined the baseline characteristics of the 4372 participants by gender and CHD status at the end of Descriptive statistics were obtained and compared by 2 test or independent t test between participants who developed CHD during the average 10- year follow-up and those who did not. Ten-year incidence rates of CHD in subgroups of the variables by gender were also examined along with the distributions of CHD event free time, which provided preliminary information on the significant risk factors. The log-rank test 12 was used to compare the distributions of time to CHD. Consequently, Cox proportional hazards models 13 were fitted to the data with categories of all the significant risk factors to provide information of the hazard ratios between subcategories. Because CHD risk differs between men and women, prediction equations were developed by gender. We first considered the significant variables that are commonly measured in the clinic, ie, age, blood pressure, LDL-C, HDL-C, diabetes status, albuminuria, and cigarette smoking status. We also considered fibrinogen and ECG-evident left ventricular hypertrophy (ECG-LVH). Because fibrinogen is not assessed routinely in most clinics and the ECG is not a routine screening procedure, these variables are of limited use in clinical prediction of CHD. We therefore will only report briefly the findings and will not present any prediction models that include ECG-LVH or fibrinogen. The second set of models was similar to the first except that TC and HDL-C were used instead of LDL-C and HDL-C. The Cox proportional hazards model with the significant risk factors (or covariates) was used to develop the prediction equations. Age, SBP, TC, LDL-C, and HDL-C were treated as continuous variables in the equations. With the use of the estimated coefficients, an equation that estimates the probability of developing CHD in a certain number of years was derived. The mathematical details are given in the online-only Data Supplement. The estimated probabilities of developing CHD in 10 years based on this equation are provided on the SHS Web site ( Discrimination, Calibration, and Validation of the Prediction Equations We used methods that account for the CHD-free time to assess calibration and discrimination. To assess the ability of the prediction

3 Lee et al CHD Prediction Equation 2899 equations to discriminate patients who develop CHD from those who do not, we used a version of the c statistic, which was calculated on the basis of all usable pairs of participants. 14 Analogous to the area under the receiver operating characteristic curve, c represents an estimate of the probability that the equation assigns a higher risk to participants who develop CHD early in the follow-up period (10 years) than to those who develop CHD late or never develop the disease in the follow-up period. A c value of 0.7 indicates good discrimination ability, and the closer the c value is to 1.0, the better is the discrimination ability. The performance of the developed equations was also assessed for calibration by the use of a version of the Hosmer-Lemeshow statistic. 14 Participants were divided into deciles according to their predicted risk of CHD in 10 years with the use of the proposed equations, and the Hosmer-Lemeshow statistic was calculated to compare the differences between the predicted and actual proportions of CHD events. Values of such statistics 20 are considered good calibration. We used D(orig) to denote the c statistic or the probability value for the Hosmer-Lemeshow statistic obtained by applying the developed prediction equation to the original cohort that was used to derive the equation. In addition, the generated equations were validated internally with the use of bootstrapping methods. 14,15 Samples of the same size as the original cohort (n 4273) were taken with replacement 1000 times from the original cohort. The procedure was to select 4273 individuals from the original cohort 1 at a time with replacement. This procedure was then repeated 1000 times. For each of these 1000 samples, the following analyses were performed: (1) the proportional hazards model was fitted, coefficients were estimated, and a prediction equation was generated; (2) the c statistic and the probability value for the Hosmer-Lemeshow statistic were calculated [denoted by D(boot)]; and (3) the prediction equation generated in analysis 1 was then applied to the original cohort, and a c statistic and the probability value for the Hosmer-Lemeshow statistic were obtained. Let D(apply) denote the c statistic or the probability value obtained in analysis 3. The bootstrap-corrected performance of the original CHD prediction equation was assessed by the difference between D(orig) and the average of the differences, D(boot) D(apply), from the 1000 bootstrap samples. The difference [D(boot) D(apply)] is called the optimism in the fit from the bootstrap samples. 14 Let O denote the average of the 1000 optimism values, then D(orig) O is an estimate of internal validation. The smaller the value of O is, the better is the validity of the developed prediction equation. The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written. Results At the end of 2001, among the 4372 participants who were CHD free at the baseline examination, 724 (375 women and 349 men) had developed CHD. Table 1 gives summary statistics of several covariates at baseline by gender and CHD status at the end of In men, the participants who developed CHD were significantly older; had significantly higher average SBP, DBP, TC, LDL-C, fibrinogen, and log(urinary albumin/creatinine ratio); had higher prevalence of diabetes, macroalbuminuria, and microalbuminuria; and had significantly lower HDL-C. Results from women were similar except that the participants who developed CHD did not have significantly higher DBP but had higher prevalence of ECG-LVH. Risk Factors and Incident CHD Table 2 gives the number of CHD events, person-years of follow-up, and incidence per 1000 person-years by gender and subcategories of the covariates. All of the variables were significantly related to the CHD-free time except current cigarette smoking and ECG-LVH (in men only). CHD incidence increased with increasing age, blood pressure, TC, LDL-C, fibrinogen, severity of albuminuria, and decreasing HDL-C in both genders. Women and men with diabetes had 3 times and 2 times higher CHD incidence than those without, respectively. To identify important predictive variables, age, body mass index, SBP, DBP, HDL-C, LDL-C, and fibrinogen were first treated as continuous variables in a Cox proportional hazards model with categorical variables: diabetes status, current smoking status, microalbuminuria and macroalbuminuria, and ECG-LVH. The stepwise variable selection procedure identified age, SBP, DBP, HDL-C, LDL-C, diabetes status, current smoking status, and albuminuria as significant risk factors for CHD. We also combined SBP, DBP, and antihypertensive treatment into a categorical variable blood pressure with 3 categories: normal, prehypertension, and hypertension. A proportional hazards model was fitted with all of the aforementioned significant risk factors as categorical variables. Table 3 gives the estimated coefficients, standard errors, probability values, and hazard ratios (relative risks) with their 95% confidence intervals (CIs) of these 7 risk factors. Women who were 65 to 74 years old, who had LDL-C 160 mg/dl, who had diabetes, and who had macroalbuminuria had 2 times higher risk of developing CHD in 10 years than their respective reference groups. Men who were between 65 and 74 years of age, who had hypertension, whose LDL-C was 160 mg/dl, or who had macroalbuminuria had 2-fold higher risk of developing CHD in 10 years. Development of Risk Prediction Equations A number of models were considered in the process of developing the most appropriate predictive equations, including models with various forms of the significant risk factors, for example, treating age as a continuous variable; replacing categorical hypertension with continuous SBP and DBP measurements; considering age, SBP, DBP, LDL-C, and HDL-C as continuous variables; and use of hypertension medication, diabetes status, current smoking status, microalbuminuria, and macroalbuminuria as categorical variables with and without interaction terms such as age LDL-C, age HDL-C, age SBP, age DBP, and ln(albumin/creatinine) diabetes. None of the interaction terms were found to be significant in either men or women after having age, SBP, DBP, LDL-C, HDL-C (all as continuous variables), use of hypertension medication, diabetes status, current smoking status, microalbuminuria, and macroalbuminuria in the model. The model that included age, SBP, LDL-C, HDL-C (all as continuous variables), use of hypertension medication, diabetes, smoking status, microalbuminuria, and macroalbuminuria was found to be most appropriate on the basis of the c statistic. Categorizing some or all of the continuous variables or including DBP in the model did not increase the c statistic by any meaningful amount. We therefore propose this model for practical use. The equation is given in the online Data Supplement.

4 2900 Circulation June 27, 2006 TABLE 1. Baseline Characteristics by Gender and CHD Status at the End of 2001 CHD No Yes Variable No. Mean/% SD No. Mean/% SD P Women Age, y BMI SBP, mm Hg DBP, mm Hg TC, mg/dl LDL-C, mg/dl HDL-C, mg/dl Fibrinogen Diabetes (ADA) Current smoking Log (urinary albumin/creatinine) Microalbuminuria Macroalbuminuria ECG-LVH CHD-free time (years) Men Age, y BMI SBP, mm Hg DBP, mm Hg TC, mg/dl LDL-C, mg/dl HDL-C, mg/dl Fibrinogen Diabetes (ADA) Current smoking Log (urinary albumin/creatinine) Microalbuminuria Macroalbuminuria ECG-LVH CHD-free time, y ADA indicates American Diabetes Association. SI conversions: To convert TC, LDL-C, and HDL-C to mmol/l, multiply by Table 4 gives the estimated coefficients underlying the CHD prediction equations we propose for men and women. For example, the exponent term in Equation 1 in the online Data Supplement for men was as follows: b i x i age (if hypertension medication is used) SBP LDL-C HDL- C (if diabetes present) (if current smoker) (if microalbuminuria present) (if macroalbuminuria present) For a continuous variable (or risk factor), exp(b i ) represents the increase in risk of developing CHD corresponding to a 1-unit increase (if the sign is positive) or decrease (if the sign if negative) in the variable. For example, for 1-year increase in age, the risk of CHD for men increases 5.0% [exp(0.0492) 1.050], and for every 10-unit increase in HDL-C, the risk of CHD decreases 15.3% [exp( 0.166) 0.847]. The prediction equation for women was derived in a similar manner with the use of the corresponding regression coefficients in Table 4. As an example, for a 65-year-old male smoker, who has diabetes but no albuminuria, who is on hypertension medication, and whose SBP is 140 mm Hg, LDL-C is 140 mg/dl, and HDL-C is 35 mg/dl (3.63 and 0.91 mmol/l), the estimated probability of developing CHD in 10 years would be 57% (95% CI, 43% to 68%). On the other hand, a nonsmoking man without diabetes or albuminuria at the same age,

5 Lee et al CHD Prediction Equation 2901 TABLE 2. CHD Incidence (per 1000 Person-Years) According to Different Risk Factor Categories Women Men No. No. of CHD % Person-Years CHD Incidence No. No. of CHD % Person-Years CHD Incidence Age group [45, 55) [55, 65) [65, 75) Blood pressure Normal Prehypertension Hypertension TC, mg/dl [200, 240) LDL-C, mg/dl [100, 130) [130, 160) HDL-C, mg/dl [40, 60) Diabetes (ADA) No Yes Current smoking No Yes Albuminuria Normal Microalbuminuria Macroalbuminuria Fibrinogen* % (33.3, 66.7%] % ECG-LVH No Yes ADA indicates American Diabetes Association. Square brackets indicate inclusive bounds; round brackets, exclusive bounds. SI conversions: To convert TC, LDL-C, and HDL-C to mmol/l, multiply by *For men, 253, , 306; for women, 275, , 336. P from the log-rank test for comparing survival curves among categories of the variable. whose SBP is 110 mm Hg, LDL-C is 110 mg/dl, and HDL-C is 60 mg/dl (2.85 and 1.55 mmol/l), would have a risk of only 11% (95% CI, 7% to 14%) to develop CHD in 10 years. Similarly, for women, a prediction equation was developed with the use of the estimated coefficients from the proportional hazards model given in Table 4. The Hosmer-Lemeshow statistics yielded by these equations were 7.18 (P 0.45) and 7.25 (P 0.51) for men and women, respectively, indicating good agreement between the observed and predicted number of CHD events in 10 years or good calibration. The c statistics were 0.73 for women and 0.71 for men, indicating good discrimination

6 2902 Circulation June 27, 2006 TABLE 3. Cox Proportional Hazards Model for CHD-Free Time 95% Hazard Confidence Limits Variable Parameter Estimate SE P Hazard Ratio Lower Upper Women Age group [45, 55) Referent [55, 65) [65, 75) Blood pressure Normal Referent Prehypertension Hypertension LDL-C, mg/dl 100 Referent [100, 130) [130, 160) HDL-C, mg/dl [40, 60) Referent Diabetes (ADA) Current smoking Albuminuria Normal Referent Microalbuminuria Macroalbuminuria Men Age group [45, 55) Referent [55, 65) [65, 75) Blood pressure Normal Referent Prehypertension Hypertension LDL-C, mg/dl 100 Referent [100, 130) [130, 160) HDL-C, mg/dl [40, 60) Referent Diabetes (ADA) Current smoking Albuminuria Normal Referent Microalbuminuria Macroalbuminuria ADA indicates American Diabetic Association. Square brackets indicate inclusive bounds, round brackets, exclusive bounds. SI conversions: To convert TC, LDL-C, and HDL-C to mmol/l, multiply by

7 Lee et al CHD Prediction Equation 2903 TABLE 4. -Coefficients Underlying CHD Prediction Equations Using LDL-C and HDL-C Using TC and HDL-C Variable Men Women Men Women Age Hypertension medication SBP LDL-C or TC, mg/dl HDL-C, mg/dl Diabetes Current smoking Microalbuminuria Macroalbuminuria S o (10): baseline survival function at t ability. The internal validation results in which the bootstrapping method was used showed a bootstrap-corrected c statistic of 0.70 (with an O value of ) for men and 0.72 (O ) for women. The small O values indicate good internal validation. The probability value for the Hosmer-Lemeshow statistic was 0.60 (O 0.147) for men and 0.71 (O 0.198) for women. These Hosmer- Lemeshow probability values and c statistics indicated good calibration and discrimination ability. To investigate whether fibrinogen and ECG-LVH warranted further consideration, we added these 2 variables to the proportional hazards model with the aforementioned 7 significant clinically available risk factors. It was found that, after adjustment for the clinical variables in the proposed equation, neither fibrinogen nor ECG-LVH was significant in either men or women. Significance levels for the other 7 covariates were similar to those given in Table 4. Table 4 also gives the estimated coefficients in the Cox model when TC and HDL-C were used instead of LDL-C and HDL-C. Estimated probabilities of developing CHD in 10 years by gender can be calculated by following the same aforementioned procedure. The discrimination ability of these equations was similar to those equations in which LDL-C and HDL-C were used, as indicated by the c statistics (0.70 for men and 0.73 for women). However, calibration was moderate to good, as indicated by the Hosmer-Lemeshow 2 statistics of (P 0.164) for men and (P 0.041) for women. The internal validation results in which the bootstrap method was used showed that the bootstrap-corrected c statistic was 0.68 (O ) for men and 0.73 (O ) for women, and the probability value for the Hosmer-Lemeshow statistic was (O 0.218) for men and (O 0.158) for women. Again, when fibrinogen and ECG-LVH were included as potential risk factors, neither was significant in either gender. A major new finding in the SHS was that albuminuria is an independent significant risk factor for CHD in the American Indian population, with macroalbuminuria having a stronger effect than microalbuminuria. The effects of diabetes may be stronger in American Indian populations than in the general population. For example, when age, blood pressure, TC, HDL-C, diabetes, and smoking were used as covariates, the estimated regression coefficients for diabetes as a predictor of CHD in the SHS were for men and for women. These coefficients, adjusted for the other covariates, are 68% for men and 89% for women, larger than those obtained in the FHS ( and , respectively). 1 This was also reflected in the higher adjusted hazard ratio (or relative risk) associated with diabetes in the SHS, particularly in women (1.98 for men and 2.95 for women versus 1.50 and 1.77 in the FHS 1 ). In men, high total cholesterol had a stronger effect on CHD in the SHS participants than in the FHS participants. The risk of developing CHD for men whose cholesterol levels were 240 mg/dl (6.22 mmol/l) was 2.7 times that of men whose cholesterol levels were 200 mg/dl (5.18 mmol/l), which was much larger than the 1.9-fold increase in the FHS. Although blood pressures seem to be less affected by obesity and hyperinsulinemia in American Indians compared with other populations, 16 the effects of hypertension among the SHS participants were similar to those in the FHS. Discussion Cardiovascular disease was rare among American Indians decades ago. However, in recent years, the rates of CHD in this population have exceeded those in other populations. The SHS participants who are members of 13 American Indian tribes in 3 of the regions with the largest American Indian populations are representative of the American Indian tribes in these regions. Therefore, we believe that the prediction equations developed with the use of the 10-year follow-up data from these SHS participants are reasonably applicable to a large proportion of the American Indian population. We took advantage of the Internet to provide a risk calculator on the SHS Web site for convenient reference. Although Internet access may not be available to every American Indian, it is available to most, if not all, tribal offices and providers who deliver healthcare to American

8 2904 Circulation June 27, 2006 Indians. Users can log on to the SHS Web site and select the link to risk calculator. The risk calculator asks the user to enter the values or status of the risk factors. After these values are entered, an estimated probability of developing CHD in 10 years will be given immediately. We understand that all risk schemes perform better in the cohort in which they are derived. The best assessments we could perform were with the use of the c statistic for discrimination ability, the Hosmer-Lemeshow statistic for calibration, and the bootstrapping method for internal validation (because there are no other similar longitudinal data of 10 years for us to validate our equations). All of the assessment results were reasonably good. The equations proposed in this article were derived with the use of data over an average of 10 years of follow-up from men and women aged 45 to 74 years, and therefore we cannot assess its utility in younger individuals. These equations may be applicable to other ethnic groups with similar propensity for diabetes. In this regard, several issues must be considered. A large percentage of the participants were either overweight (26% in men and 31% in women) or obese (36% in men and 41% in women), and the average level of physical activities was low (38% of men and 40% of women reported no physical activity during past week 17 ). Obesity and physical activity were not included in the equation because they were not significant. An explanation is that obesity and inactivity may lead to diabetes. Thus, the effects of these proximal risk factors disappeared after adjustment for diabetes. Albuminuria was found to be a significant independent predictor of CHD in this population, after adjustment for conventional risk factors including diabetes. The probability of developing CHD increased considerably in participants with albuminuria, particularly macroalbuminuria. For a man who had macroalbuminuria, the probability of developing CHD is twice that of a man without albuminuria with exactly the same other risk factors, and in women the effect is even greater. Thus, the contribution of macroalbuminuria to CHD is crucial and cannot be ignored in this population. Albuminuria should be considered in other populations with a high rate of diabetes, and the proposed equations should have potential applicability to other populations with high prevalence of diabetes. Because of the differences in the impact of these risk factors among American Indians, the proposed equations and the resulting individual projections have particular value for healthcare providers of this population. The equations will afford clinicians the opportunity to easily calculate an American Indian specific CHD risk that can be used in patient and family education as well as in decision making about modifications of their risk intervention goals and therapies. For example, a high estimated risk may prompt the clinician to examine carefully all of the risk factors for the patient and modify or intensify the treatment plan for some risk factors that may have otherwise been considered less important. Indeed, providers within the Indian health system initially requested the development of these equations to better evaluate patient risk and intervene more appropriately. Healthcare providers in the American Indian health system plan to incorporate these equations broadly into the risk calculators within their cardiovascular disease management system, which is an electronic reminder system that automatically populates registries of levels of cardiovascular disease risk for specific prevention interventions as well as a patient information system for patient handouts related to risk modification opportunities. We hope that the equations and particularly the calculated probabilities are useful to healthcare providers of the American Indian population and that they will be considered for use in other similar populations. Acknowledgments The authors acknowledge the support, assistance, and cooperation of the Ak-Chin Tohono O Odham (Papago)/Pima, Apache, Caddo, Cheyenne River Sioux, Comanche, Delaware, Fort Sill Apache, Gila River Pima/Maricopa, Kiowa, Oglala Sioux, Salt River Pima/Maricopa, Spirit Lake Sioux, and Wichita Indian tribes and communities and the participation of their members in the SHS. The authors also acknowledge the support and assistance of the Indian Health Service hospital and clinic at each center, field directors of the Strong Heart Study clinics and their staff, and the physicians who performed the mortality and morbidity reviews. Sources of Funding This study was supported by cooperative agreement grants (U01HL , U01HL-41652, and U01HL-41654) from the National Heart, Lung, and Blood Institute. None. Disclosures References 1. Wilson PW, D Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97: D Agostino RB, Grundy S, Sullivan LM, Wilson PW. Validation of the Framingham coronary heart disease prediction scores, results of a multiple ethic groups investigation. JAMA. 2001;286: Howard BV, Lee ET, Cowan LD, Devereux RB, Galloway JM, Go OT, Howard WJ, Rhoades ER, Robbins DC, Sievers ML, Welty TK. Rising tide of cardiovascular disease in American Indians: the Strong Heart Study. Circulation. 1999;99: Lee ET, Cowan LD, Howard WJ, Sievers M, Welty TK, Wang W, Yeh JL, Rhoades ER, Devereux RB, Fabsitz RR, Go OT, Howard BV. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged years, : the Strong Heart Study. Am J Epidemiol. 1998;147: Lee ET, Welty TK, Fabsitz R, Cowan LD, Lee N-A, Oopik AJ, Cucchiara AJ, Savage PJ, Howard BV. The Strong Heart Study: a study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol. 1990;132: Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Evaluation, and Treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes. 1997;20: von Clauss A. Gerinnungsphysiologishe Schnell methode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17: National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:

9 Lee et al CHD Prediction Equation The National Heart, Lung and Blood Institute, The Strong Heart Study Coordinating Center. Strong Heart Study Operations Manual. Oklahoma City, Okla: University of Oklahoma Health Sciences Center; Howard BV, Lee ET, Cowan LD, Fabsitz RR, Howard WJ, Oopik AJ, Robbins DC, Savage PJ, Yeh JL, Welty TK. Coronary heart disease prevalence and its relation to risk factors in American Indians: the Strong Heart Study. Am J Epidemiol. 1995;142: Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc. 1972;series A(135): Cox D. Regression models and life tables. J R Stat Soc. 1972;34: Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15: Efron B. Bootstrap method: another look at the jackknife. Ann Stat. 1979;7: Howard BV, Lee ET, Yeh JL, Go OT, Fabsitz RR, Devereux RB, Welty TK. Hypertension in adult American Indians: the Strong Heart Study. Hypertension. 1996;28: Welty TK, Lee ET, Yeh J, Cowan LD, Go O, Fabsitz RR, Lee N-A, Oopik AJ, Robbins RC, Howard BV. Cardiovascular disease risk factors among American Indians: the Strong Heart Study. Am J Epidemiol. 1995;142: CLINICAL PERSPECTIVE The proposed coronary heart disease (CHD) prediction equations are derived from a large cohort of American Indians, aged 45 to 74 years, who participated in the Strong Heart Study and therefore are specifically applicable to middle-aged and senior American Indians. The American Indian population is known to have high prevalence of diabetes and albuminuria. Thus, the proposed equations, which include diabetes and albuminuria as major CHD predictive factors, have a high potential of applicability to other ethnic populations in which the prevalence proportions of diabetes and albuminuria are high. Clinicians can use the prediction equations as a patient education tool to advise the patients (and their families) how they can reduce the risk of CHD by modifying their health behaviors or lifestyles and consequently improve their risk factors. They can also teach their patients to monitor their own CHD risk by using the user-friendly online risk calculator. A high risk could prompt them to change their health behaviors, and a reduced risk would encourage them to continue the healthy habits or improve even more. The prediction equations provide an overall prediction on CHD outcomes based on the most important risk factors. They can serve as an aide to the clinicians in determining intervention goals and treatment strategies for their patients. For example, a high estimated risk may prompt the clinician to examine carefully all of the risk factors for the patient and modify or intensify the treatment plan for some risk factors that may have otherwise been considered less important.

Rising Tide of Cardiovascular Disease in American Indians. The Strong Heart Study

Rising Tide of Cardiovascular Disease in American Indians. The Strong Heart Study Rising Tide of Cardiovascular Disease in American Indians The Strong Heart Study Barbara V. Howard, PhD; Elisa T. Lee, PhD; Linda D. Cowan, PhD; Richard B. Devereux, MD; James M. Galloway, MD; Oscar T.

More information

Tobacco Use and Cardiovascular Disease among American Indians: The Strong Heart Study

Tobacco Use and Cardiovascular Disease among American Indians: The Strong Heart Study Int. J. Environ. Res. Public Health 2010, 7, 3816-3830; doi:10.3390/ijerph7103816 OPEN ACCESS Article International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph

More information

LDL Cholesterol as a Strong Predictor of Coronary Heart Disease in Diabetic Individuals With Insulin Resistance and Low LDL. The Strong Heart Study

LDL Cholesterol as a Strong Predictor of Coronary Heart Disease in Diabetic Individuals With Insulin Resistance and Low LDL. The Strong Heart Study LDL Cholesterol as a Strong Predictor of Coronary Heart Disease in Diabetic Individuals With Insulin Resistance and Low LDL The Strong Heart Study Barbara V. Howard, David C. Robbins, Maurice L. Sievers,

More information

STRONG HEART STUDY DATA BOOK

STRONG HEART STUDY DATA BOOK Division of Epidemiology and Clinical Applications STRONG HEART STUDY DATA BOOK A REPORT TO AMERICAN INDIAN COMMUNITIES N A T I O N A L I N S T I T U T E S O F H E A L T H N A T I O N A L H E A R T, L

More information

YOUNG ADULT MEN AND MIDDLEaged

YOUNG ADULT MEN AND MIDDLEaged BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,

More information

Hypertension is an important factor in premature death,

Hypertension is an important factor in premature death, Effect of Hypertension on Mortality in Pima Indians Maurice L. Sievers, MD; Peter H. Bennett, MB, MRCP, FFCM; Janine Roumain, MD, MPH; Robert G. Nelson, MD, PhD Background The effect of hypertension on

More information

Combined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve Prediction of Mortality in American Indians

Combined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve Prediction of Mortality in American Indians Combined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve rediction of Mortality in American Indians The Strong Heart Study eter M. Okin, Mary J. Roman, Elisa

More information

I nsulin resistance plays a major role in

I nsulin resistance plays a major role in Pathophysiology/Complications O R I G I N A L A R T I C L E Insulin Resistance, Incident Cardiovascular Diseases, and Decreased Kidney Function Among Nondiabetic American Indians The Strong Heart Study

More information

Relationship of High and Low Ankle Brachial Index to All-Cause and Cardiovascular Disease Mortality

Relationship of High and Low Ankle Brachial Index to All-Cause and Cardiovascular Disease Mortality Relationship of High and Low Ankle Brachial Index to All-Cause and Cardiovascular Disease Mortality The Strong Heart Study Helaine E. Resnick, PhD, MPH; Robert S. Lindsay, MB, PhD; Mary McGrae McDermott,

More information

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program

More information

Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes

Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes The Strong Heart Study WEIQUAN LU, MD HELAINE E. RESNICK,

More information

F asting plasma glucose (FPG) has been. Hemoglobin A1C, Fasting Glucose, and Cardiovascular Risk in a Population With High Prevalence of Diabetes

F asting plasma glucose (FPG) has been. Hemoglobin A1C, Fasting Glucose, and Cardiovascular Risk in a Population With High Prevalence of Diabetes Epidemiology/Health Services Research O R I G I N A L A R T I C L E Hemoglobin A1C, Fasting Glucose, and Cardiovascular Risk in a Population With High Prevalence of Diabetes The Strong Heart Study HONG

More information

Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex

Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Prevention and Rehabilitation Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Nathan D. Wong, PhD, a Gaurav Thakral, BS, a Stanley S. Franklin,

More information

The Framingham Risk Score (FRS) is widely recommended

The Framingham Risk Score (FRS) is widely recommended C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore

More information

Epidemiology. C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes The Strong Heart Study

Epidemiology. C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes The Strong Heart Study Epidemiology C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes The Strong Heart Study Lyle G. Best, MD; Ying Zhang, PhD; Elisa T. Lee, PhD; Jeun-Liang

More information

The Effect of Estrogen Use on Levels of Glucose and Insulin and the Risk of Type 2 Diabetes in American Indian Postmenopausal Women

The Effect of Estrogen Use on Levels of Glucose and Insulin and the Risk of Type 2 Diabetes in American Indian Postmenopausal Women Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E The Effect of Estrogen Use on Levels of Glucose and Insulin and the Risk of Type 2 Diabetes in American Indian Postmenopausal

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama

More information

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

C-Reactive Protein and Electrocardiographic ST-Segment Depression Additively Predict Mortality The Strong Heart Study

C-Reactive Protein and Electrocardiographic ST-Segment Depression Additively Predict Mortality The Strong Heart Study Journal of the American College of Cardiology Vol. 45, No. 11, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.02.072

More information

Cardiovascular disease (CVD) is now

Cardiovascular disease (CVD) is now Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Regional Variation in Cardiovascular Disease Risk Factors Among American Indians and Alaska Natives With Diabetes STEPHEN

More information

Chronic kidney disease (CKD) has received

Chronic kidney disease (CKD) has received Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:

More information

The Whitehall II study originally comprised 10,308 (3413 women) individuals who, at

The Whitehall II study originally comprised 10,308 (3413 women) individuals who, at Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.

More information

NORTHWEST TRIBAL BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) PROJECT

NORTHWEST TRIBAL BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) PROJECT 111 NORTHWEST TRIBAL BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) PROJECT APPENDIX 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140

More information

Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes

Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,

More information

Although the prevalence and incidence of type 2 diabetes mellitus

Although the prevalence and incidence of type 2 diabetes mellitus n clinical n Validating the Framingham Offspring Study Equations for Predicting Incident Diabetes Mellitus Gregory A. Nichols, PhD; and Jonathan B. Brown, PhD, MPP Background: Investigators from the Framingham

More information

Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S.

Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S. Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S. Item Type Thesis Authors Couch, Christopher Rights Copyright is held by the author.

More information

Donald M. Lloyd-Jones, MD, ScM a,b, *, Alan R. Dyer, PhD a, Renwei Wang, MS a, Martha L. Daviglus, MD, PhD a, and Philip Greenland, MD a,b

Donald M. Lloyd-Jones, MD, ScM a,b, *, Alan R. Dyer, PhD a, Renwei Wang, MS a, Martha L. Daviglus, MD, PhD a, and Philip Greenland, MD a,b Risk Factor Burden in Middle Age and Lifetime Risks for Cardiovascular and Non-Cardiovascular Death (Chicago Heart Association Detection Project in Industry) Donald M. Lloyd-Jones, MD, ScM a,b, *, Alan

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Diabetes Care 34: , 2011

Diabetes Care 34: , 2011 Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Obesity in Adults Is Associated With ReducedLungFunctioninMetabolic Syndrome and Diabetes The Strong Heart Study FAWN YEH, PHD 1 ANNE E.

More information

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:

More information

Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study

Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study 1/5 Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge

More information

Diabetes MAYER B. DAVIDSON, MD,* CO-EDITOR-IN-CHIEF; HENRY N. GINSBERG, MD, REVIEWER; TERRENCE F. FAGAN, MANAGING EDITOR; CHING-LING CHEN, PhD, WRITER

Diabetes MAYER B. DAVIDSON, MD,* CO-EDITOR-IN-CHIEF; HENRY N. GINSBERG, MD, REVIEWER; TERRENCE F. FAGAN, MANAGING EDITOR; CHING-LING CHEN, PhD, WRITER Professional Postgraduate Services Release Date: March 14, 2008 Valid Through: July 14, 2008 Sponsor This educational activity is a component of the National Diabetes Education Initiative (NDEI ), sponsored

More information

The Framingham Coronary Heart Disease Risk Score

The Framingham Coronary Heart Disease Risk Score Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

EXAMINING THE EDUCATION GRADIENT IN CHRONIC ILLNESS

EXAMINING THE EDUCATION GRADIENT IN CHRONIC ILLNESS EXAMINING THE EDUCATION GRADIENT IN CHRONIC ILLNESS PINKA CHATTERJI, HEESOO JOO, AND KAJAL LAHIRI Department of Economics, University at Albany: SUNY February 6, 2012 This research was supported by the

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

Statistical Fact Sheet Populations

Statistical Fact Sheet Populations Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total

More information

etable 3.1: DIABETES Name Objective/Purpose

etable 3.1: DIABETES Name Objective/Purpose Appendix 3: Updating CVD risks Cardiovascular disease risks were updated yearly through prediction algorithms that were generated using the longitudinal National Population Health Survey, the Canadian

More information

Established Risk Factors for Coronary Heart Disease (CHD)

Established Risk Factors for Coronary Heart Disease (CHD) Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Randomized Design of ALLHAT BP Trial

Randomized Design of ALLHAT BP Trial Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive

More information

Identification of subjects at high risk for cardiovascular disease

Identification of subjects at high risk for cardiovascular disease Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet

More information

Blood Pressure Assessment Practices of Dental Hygienists

Blood Pressure Assessment Practices of Dental Hygienists Blood Pressure Assessment Practices of Dental Hygienists Abstract An estimated 50 million Americans have high blood pressure (HBP), with 30% of them unaware of their condition. Both the American Dental

More information

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner

More information

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk

More information

Epidemiologic Measure of Association

Epidemiologic Measure of Association Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2

More information

DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid

DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid Malaysian Journal of Medical Sciences, Vol. 11, No. 1, January 2004 (44-51) ORIGINAL ARTICLE DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul

More information

Risk Factor Clustering in the Insulin Resistance Syndrome

Risk Factor Clustering in the Insulin Resistance Syndrome American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 148, No. 9 Printed in U.S.A. Risk Factor Clustering in the Insulin

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria 1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rawshani Aidin, Rawshani Araz, Franzén S, et al. Risk factors,

More information

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised

More information

Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis

Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

International Journal of Pharma and Bio Sciences

International Journal of Pharma and Bio Sciences Research Article Biochemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 CORRELATION BETWEEN SERUM URIC ACID LEVELS AND NON HDL CHOLESTEROL IN TYPE II DIABETES MELLITUS AN OBSERVATIONAL

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Prospective Analysis of Mannose-Binding Lectin Genotypes and Coronary Artery Disease in American Indians

Prospective Analysis of Mannose-Binding Lectin Genotypes and Coronary Artery Disease in American Indians Prospective Analysis of Mannose-Binding Lectin Genotypes and Coronary Artery Disease in American Indians The Strong Heart Study Lyle G. Best, MD; Michael Davidson, MD, MPH, PhD; Kari E. North, PhD; Jean

More information

Comparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study

Comparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study 80 Comparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study Thomas Truelsen, MB; Ewa Lindenstrtfm, MD; Gudrun Boysen, DMSc Background and Purpose We wished to

More information

Elevated blood pressure (BP) is a major modifiable risk factor

Elevated blood pressure (BP) is a major modifiable risk factor Blood Pressure in Adulthood and Life Expectancy With Cardiovascular Disease in Men and Women Life Course Analysis Oscar H. Franco, Anna Peeters, Luc Bonneux, Chris de Laet Abstract Limited information

More information

Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus

Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus 1 Dissertation Title Page: Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus Qian Shi, MPH, PhD candidate Department of Global Health Management

More information

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive

More information

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

Diabetes increases the risk of both

Diabetes increases the risk of both Pathophysiology/Complications O R I G I N A L A R T I C L E Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease in Nondiabetic American Indians The Strong Heart Study

More information

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients

More information

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01. NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic

More information

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain) Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension

More information

Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women

Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women European Heart Journal (2002) 23, 528 535 doi:10.1053/euhj.2001.2888, available online at http://www.idealibrary.com on Combined effects of systolic blood pressure and serum cholesterol on cardiovascular

More information

Supplemental tables/figures

Supplemental tables/figures Supplemental tables/figures Table S:Baseline variables included in calculation of QRISK and Framingham scores Ethnicity (European, Indian Pakistani, Bangladeshi, Black African, Black Caribbean) QRISK Age,

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

the U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations

the U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations Cardioprotection: What is it? Who needs it? William B. Kannel, MD, MPH From the Department of Preventive Medicine and Epidemiology, Evans Department of Clinical Research, Boston University School of Medicine,

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

Baldness and Coronary Heart Disease Rates in Men from the Framingham Study

Baldness and Coronary Heart Disease Rates in Men from the Framingham Study A BRIEF ORIGINAL CONTRIBUTION Baldness and Coronary Heart Disease Rates in Men from the Framingham Study The authors assessed the relation between the extent and progression of baldness and coronary heart

More information

Risk modeling for Breast-Specific outcomes, CVD risk, and overall mortality in Alliance Clinical Trials of Breast Cancer

Risk modeling for Breast-Specific outcomes, CVD risk, and overall mortality in Alliance Clinical Trials of Breast Cancer Risk modeling for Breast-Specific outcomes, CVD risk, and overall mortality in Alliance Clinical Trials of Breast Cancer Mary Beth Terry, PhD Department of Epidemiology Mailman School of Public Health

More information

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial 1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.

More information

Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese

Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,

More information

Introduction. RS Gray 1, RR Fabsitz 2, LD Cowan 3, ET Lee 3, TK Welty 4, KA Jablonski 1 and BV Howard 1 *

Introduction. RS Gray 1, RR Fabsitz 2, LD Cowan 3, ET Lee 3, TK Welty 4, KA Jablonski 1 and BV Howard 1 * (2000) 24, 849±860 ß 2000 Macmillan Publishers Ltd All rights reserved 0307±0565/00 $15.00 www.nature.com/ijo Relation of generalized and central obesity to cardiovascular risk factors and prevalent coronary

More information

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Cardiovascular Disease Prevention: Current Knowledge, Future Directions Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal

More information

Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal

Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal Koju R, Gurung R, Pant P, Humagain S, Yogol CM, Koju A, Manandhar K, Karmacharya B, Bedi TRS Address for Correspondence:

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure

More information

Downloaded from ijdld.tums.ac.ir at 19:13 IRDT on Friday May 4th 2018

Downloaded from ijdld.tums.ac.ir at 19:13 IRDT on Friday May 4th 2018 - : -. : - 3 *. () - :.. 30 608 43 : (LDL-C) (HDL-C) TG/HDL-)HDL-C TG (TC/HDL-C)HDL-C (HRs) TC (non- HDL-C) (TG) (TC) HDL. 8/4. HR. ( 98 9). TG/HDL-C (C 89 : HDL-C.[/3 (/0 -/57)] TC/HDL-C. ( C ) WHO non-hdl-

More information

How to Reduce CVD Complications in Diabetes?

How to Reduce CVD Complications in Diabetes? How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year

More information

CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS

CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION by PAUL E. DRAWZ, MD, MHS Submitted in partial fulfillment of the requirements for the degree of Master

More information

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This

More information

Stop Atherosclerosis in Native Diabetics Study (SANDS): Baseline Characteristics of the Randomized Cohort

Stop Atherosclerosis in Native Diabetics Study (SANDS): Baseline Characteristics of the Randomized Cohort JOURNAL OF HD RP Journal of Health Disparities Research and Practice Volume 3, Number 1, Spring 2009, pp. 29 42 2009 Center for Health Disparities Research School of Community Health Sciences University

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

Why Do We Treat Obesity? Epidemiology

Why Do We Treat Obesity? Epidemiology Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population

More information

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes

Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes Gordon L Jensen, MD, PhD Senior Associate Dean for Research Professor of Medicine and Nutrition Objectives Health outcomes

More information